AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
Microarrays in primary breast cancer - lessons from chemotherapy studies
Authors: Lonning, PE Sorlie, T Perou, CM Brown, PO Botstein, D Borresen-Dale, AL
Citation: Pe. Lonning et al., Microarrays in primary breast cancer - lessons from chemotherapy studies, ENDOCR-R CA, 8(3), 2001, pp. 259-263
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer
Authors: Geisler, J Detre, S Berntsen, H Ottestad, L Lindtjorn, B Dowsett, M Lonning, PE
Citation: J. Geisler et al., Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer, CLIN CANC R, 7(5), 2001, pp. 1230-1236
Exemestane: a review of its clinical efficacy and safety
Authors: Lonning, PE
Citation: Pe. Lonning, Exemestane: a review of its clinical efficacy and safety, BREAST, 10(3), 2001, pp. 198-208
Pharmacokinetics and metabolism of formestane in breast cancer patients
Authors: Lonning, PE Geisler, J Johannessen, DC Gschwind, HP Waldmeier, F Schneider, W Galli, B Winkler, T Blum, W Kriemler, HP Miller, WR Faigle, JW
Citation: Pe. Lonning et al., Pharmacokinetics and metabolism of formestane in breast cancer patients, J STEROID B, 77(1), 2001, pp. 39-47
Aromatase inhibitors and inactivators in breast cancer - These potent inhibitors of oestrogen synthesis may be superior to tamoxifen
Authors: Lonning, PE
Citation: Pe. Lonning, Aromatase inhibitors and inactivators in breast cancer - These potent inhibitors of oestrogen synthesis may be superior to tamoxifen, BR MED J, 323(7318), 2001, pp. 880-881
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
Authors: Lonning, PE Taylor, PD Anker, G Iddon, J Wie, L Jorgensen, LM Mella, O Howell, A
Citation: Pe. Lonning et al., High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy, BREAST CANC, 67(2), 2001, pp. 111-116
Gene expression patterns of breast carcinomas distinguish tumor subclasseswith clinical implications
Authors: Sorlie, T Perou, CM Tibshirani, R Aas, T Geisler, S Johnsen, H Hastie, T Eisen, MB van de Rijn, M Jeffrey, SS Thorsen, T Quist, H Matese, JC Brown, PO Botstein, D Lonning, PE Borresen-Dale, AL
Citation: T. Sorlie et al., Gene expression patterns of breast carcinomas distinguish tumor subclasseswith clinical implications, P NAS US, 98(19), 2001, pp. 10869-10874
Quantitative analysis of chromosomal CGH in human breast tumors associatescopy number abnormalities with p53 status and patient survival
Authors: Jain, AN Chin, K Borresen-Dale, AL Erikstein, BK Lonning, PE Kaaresen, R Gray, JW
Citation: An. Jain et al., Quantitative analysis of chromosomal CGH in human breast tumors associatescopy number abnormalities with p53 status and patient survival, P NAS US, 98(14), 2001, pp. 7952-7957
The insulin-like growth factor system in human immunodeficiency virus infection: Relations to immunological parameters, disease progression, and antiretroviral therapy
Authors: Helle, SI Ueland, T Ekse, D Froland, SS Holly, JMP Lonning, PE Aukrust, P
Citation: Si. Helle et al., The insulin-like growth factor system in human immunodeficiency virus infection: Relations to immunological parameters, disease progression, and antiretroviral therapy, J CLIN END, 86(1), 2001, pp. 227-233
Influence of TP53 gene alterations and c-erbB-2 expression on the responseto treatment with doxorubicin in locally advanced breast cancer
Authors: Geisler, S Lonning, PE Aas, T Johnsen, H Fluge, O Haugen, DF Lillehaug, JR Akslen, LA Borresen-Dale, AL
Citation: S. Geisler et al., Influence of TP53 gene alterations and c-erbB-2 expression on the responseto treatment with doxorubicin in locally advanced breast cancer, CANCER RES, 61(6), 2001, pp. 2505-2512
Alterations in the insulin-like growth factor system during treatment withdiethylstilboestrol in patients with metastatic breast cancer
Authors: Helle, SI Geisler, J Anker, GB Leirvaag, B Holly, JMP Lonning, PE
Citation: Si. Helle et al., Alterations in the insulin-like growth factor system during treatment withdiethylstilboestrol in patients with metastatic breast cancer, BR J CANC, 85(2), 2001, pp. 147-151
Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer
Authors: Helle, SI Geisler, S Aas, T Paulsen, T Holly, JMP Lonning, PE
Citation: Si. Helle et al., Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer, BR J CANC, 85(1), 2001, pp. 74-77
Pharmacology and clinical experience with exemestane
Authors: Lonning, PE
Citation: Pe. Lonning, Pharmacology and clinical experience with exemestane, EXPERT OP I, 9(8), 2000, pp. 1897-1905
A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue
Authors: Geisler, J Berntsen, H Lonning, PE
Citation: J. Geisler et al., A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue, J STEROID B, 72(5), 2000, pp. 259-264
Clinico-pharmacological aspects of different hormone treatments
Authors: Lonning, PE
Citation: Pe. Lonning, Clinico-pharmacological aspects of different hormone treatments, EUR J CANC, 36, 2000, pp. S81-S82
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
Authors: Lonning, PE Bajetta, E Murray, R Tubiana-Hulin, M Eisenberg, PD Mickiewicz, E Celio, L Pitt, P Mita, M Aaronson, NK Fowst, C Arkhipov, A di Salle, E Polli, A Massimini, G
Citation: Pe. Lonning et al., Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial, J CL ONCOL, 18(11), 2000, pp. 2234-2244
Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy
Authors: Lien, EA Lonning, PE
Citation: Ea. Lien et Pe. Lonning, Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy, CANC TR REV, 26(3), 2000, pp. 205-227
Molecular portraits of human breast tumours
Authors: Perou, CM Sorlie, T Eisen, MB van de Rijn, M Jeffrey, SS Rees, CA Pollack, JR Ross, DT Johnsen, H Aksien, LA Fluge, O Pergamenschikov, A Williams, C Zhu, SX Lonning, PE Borresen-Dale, AL Brown, PO Botstein, D
Citation: Cm. Perou et al., Molecular portraits of human breast tumours, NATURE, 406(6797), 2000, pp. 747-752
Is there a growing role for endocrine therapy in the treatment of breast cancer?
Authors: Lonning, PE
Citation: Pe. Lonning, Is there a growing role for endocrine therapy in the treatment of breast cancer?, DRUGS, 60(1), 2000, pp. 11-21
Screening breast cancer patients for Norwegian ATM mutations
Authors: Laake, K Vu, P Andersen, TI Erikstein, B Karesen, R Lonning, PE Skovlund, E Borresen-Dale, AL
Citation: K. Laake et al., Screening breast cancer patients for Norwegian ATM mutations, BR J CANC, 83(12), 2000, pp. 1650-1653
Cross-resistance to different aromatase inhibitors in breast cancer treatment
Authors: Lonning, PE
Citation: Pe. Lonning, Cross-resistance to different aromatase inhibitors in breast cancer treatment, ENDOCR-R CA, 6(2), 1999, pp. 251-257
Effects of treatment with megestrol acetate on the insulin-like growth factor system: Time and dose dependency
Authors: Helle, SI Lundgren, S Geisler, S Ekse, D Holly, JMP Lonning, PE
Citation: Si. Helle et al., Effects of treatment with megestrol acetate on the insulin-like growth factor system: Time and dose dependency, EUR J CANC, 35(7), 1999, pp. 1070-1075
Serum homocysteine levels in postmenopausal breast cancer patients treatedwith tamoxifen
Authors: Love, RR Anker, G Yang, YH Refsum, H Ueland, PM Lonning, PE Lien, EA
Citation: Rr. Love et al., Serum homocysteine levels in postmenopausal breast cancer patients treatedwith tamoxifen, CANCER LETT, 145(1-2), 1999, pp. 73-77
Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking
Authors: Geisler, J Omsjo, IH Helle, SI Ekse, D Silsand, T Lonning, PE
Citation: J. Geisler et al., Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking, J ENDOCR, 162(2), 1999, pp. 265-270
Exemestane - A viewpoint by Per E. Lonning
Authors: Lonning, PE
Citation: Pe. Lonning, Exemestane - A viewpoint by Per E. Lonning, DRUGS, 58(4), 1999, pp. 681-681
Risultati: 1-25 | 26-28